Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Earnings Call Transcript May 6, 2025Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings Inc. (DNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Prescott Group Capital Management Phil Frohlich | 365,717 | $2,084,587 | +2% | 0.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.82 | 625,000 | Director | 2,356,874 | 2024-05-15 | Filing | |
| $0.91 | 297,619 | Director | 718,540 | 2024-05-14 | Filing | |
| $1.28 | 400,000 | Director | 1,731,874 | 2023-05-18 | Filing | |
| $1.28 | 350,000 | Director | 420,921 | 2023-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.28 | 997 | Officer | 8,819 | 2025-04-21 | Filing | |
| $7.28 | 1,244 | Officer | 45,453 | 2025-04-21 | Filing | |
| $7.73 | 395 | Officer | 8,012 | 2025-03-04 | Filing | |
| $7.73 | 790 | Officer | 34,652 | 2025-03-04 | Filing | |
| $13.44 | 367 | Officer | 7,664 | 2025-02-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,350,891 | $19,100,078 | 0.02% | |
| 2. | 1,242,035 | $7,079,602 | 0% | |
| 3. | 1,094,564 | $6,239,015 | 0.6% | |
| 4. | 311,846 | $1,777,522 | 0.03% | |
| 5. | 102,995 | $587,072 | 0% |
News See All
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript February 25, 2025Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript
Megan LeDuc: Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
10 High Risk High Reward Growth Stocks Stocks To Buy
When it comes to making money on the stock market, most investors are typically attracted to growth stocks.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2024 Earnings Call Transcript August 8, 2024Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Call Transcript
Megan LeDuc: Good evening, I’m Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I’m joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
16 Best US Stocks To Invest In Under $10
In March 2024, the S&P 500 surged with a total return of 3.2%, marking the first quarter's closure with a record high not seen since 2019.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2023 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. Ginkgo Bioworks Holdings, Inc.
Billionaire Hedge Funds
